A new study co-authored by MIT researchers finds that more than half of the drugs approved by the FDA since 2000 are connected to NIH research that would be impacted by proposed 40 percent budget cuts, reports Genetic Engineering & Biotechnology News.
Prof. Linda Griffith speaks with Nature reporter Cassandra Willyard about her work developing lab-made organoids to help study the root causes of endometriosis. Griffith has been working to develop “a model of abnormal endometrial tissue that the researchers can use to test therapies for the condition,” writes Willyard. “Because blood vessels are crucial to maintaining this tissue, Griffith knew she wanted to include them. To do this, she and her colleagues placed the organoid on a microfluidic chip surrounded by cells that form blood vessels.”
Financial Times reporter Melissa Heikkilä spotlights how MIT researchers have uncovered evidence that increased use of AI tools by medical professionals risks “leading to worse health outcomes for women and ethnic minorities.” One study found that numerous AI models “recommended a much lower level of care for female patients,” writes Heikkilä. “A separate study by the MIT team showed that OpenAI’s GPT-4 and other models also displayed answers that had less compassion towards Black and Asian people seeking support for mental health problems.”
WBUR reporter Rachell Sanchez-Smith spotlights two health tech devices being developed by Prof. Yoel Fink and Prof. Canan Dağdeviren, respectively, that aim to “give the wearers — and their doctors — a clearer picture of their overall health.” Fink has created “a thread capable of storing data, running artificial intelligence algorithms, sensing motion and sound, and communication through Bluetooth,” while Dağdeviren’s wearable ultrasound scanner can be used to make breast cancer screening “more comfortable and more accurate,” explains Sanchez-Smith.
Using AI, researchers at MIT have developed new antibiotics for gonorrhoea and MRSA, two infections that are typically hard to treat. The team “trained the AI to help it learn how bacteria was affected by different molecular structures built of atoms in order to design new antibiotics,” writes Ruth Stainer for the Daily Mail. “[A]nything too similar to the current antibiotics available, or with the potential to be toxic to human beings, was eradicated.”
Researchers at MIT used AI to “design antibiotics that can tackle hard-to-treat infections gonorrhoea and MRSA,” reports ITV News. "Our work shows the power of AI from a drug design standpoint, and enables us to exploit much larger chemical spaces that were previously inaccessible,” says Prof. James Collins.
Using generative AI, researchers at MT have designed new antibiotics to combat MRSA and gonorrhea, reports James Gallagher for the BBC. "We're excited because we show that generative AI can be used to design completely new antibiotics," says Prof. James Collins. "AI can enable us to come up with molecules, cheaply and quickly and in this way, expand our arsenal, and really give us a leg up in the battle of our wits against the genes of superbugs."
Prof. Giovanni Traverso and his lab are developing “a transdermal patch that could provide women with long-term contraception,” reports The Boston Globe Editorial Board. “The lab is also developing probiotic medications to treat abnormalities in the vaginal microbiome, a condition associated with risks including painful infection and premature birth.”
Strand Therapeutics, co-founded Jake Becraft PhD '19, has developed a programmable drug that could one day shrink tumors in cancer patients, reports Amy Feldman for Forbes. “It shocked even us,” says Becraft. “You hope something happens, but you don’t expect to see a huge response because these patients have already proven to have cancers so resistant to treatment.”
Writing for GBH, graduate students and alumni Jessica Chomik-Morales, Sarah Akaaboune, Mackenzie White '25, Celina Zhao '24, SM '25, spotlight the Dana-Farber mobile Mammogram Van. “The unit meets women where they live and work, offering care in the languages they speak,” they write. “By bringing screenings to neighborhoods with large Asian and other minority populations, the van shows how community-based, culturally responsive care can reduce disparities and improve access to critical health resources.”
Researchers at MIT are working to advance our understanding of acute Lyme disease and long Covid, reports Brianna Abbott for The Wall Street Journal. “What we’re trying to do is measure everything,” said Principal Scientist Michal Caspi Tal. “I want to find a way to give people hope.”
Interesting Engineering reporter Saoirse Kerrigan spotlights a number of MIT research projects from the past decade. MIT has “long been a hub of innovation and ingenuity across multiple industries and disciplines,” writes Kerrigan. “Every year, the school’s best and brightest debut projects that push the boundaries of science and technology. From vehicles and furniture to exciting new breakthroughs in electricity generation, the school’s projects have tackled an impressive variety of subjects.”
Prof. Giovanni Traverso speaks with WCVB about his research developing an ingestible robotic capsule capable of delivering an injection directly within the stomach. “Fifty percent of the population don’t take medication as prescribed. That’s incredible,” says Traverso. “So, if we can make a little dent, or hopefully a bigger dent, I think we can help a lot of folks out there.”
Researchers at MIT have designed an implantable device that can be used to administer a dose of glucagon to protect Type 1 diabetics from hypoglycemia, reports Amir Khollam. “The device, about the size of a quarter, sits under the skin and releases a dose of glucagon when blood sugar levels dip too low,” explains Khollam. “It can be activated manually or triggered wirelessly by a sensor.”
In a new paper, Prof. Giovanni Traverso and his colleagues highlight the results of a clinical trial that showed “a pill taken just once a week, gradually releasing medicine from within the stomach, can greatly simplify the drug schedule faced by schizophrenia patients,” writes Dennis Thompson for HealthDay News. “These final-stage clinical trial results are the product of more than 10 years of research by Traverso’s lab.”